Verastem, Inc.

NASDAQ:VSTM

Biotechnology

Healthcare
$6.87 -0.00%

-$0.00 today

Market cap
$865.72M
Beta
0.27
P/E (TTM)
-2.1
EPS (TTM)
-$1.97
52W Low $3.55High $11.25

Volume 3.97M

Average 2.58M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$137.51M

FY 2025 · Annual

Investing Cash Flow

-$9.62M

FY 2025 · Annual

Financing Cash Flow

$263.31M

FY 2025 · Annual

+380.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.2M)(73.81M)(87.37M)(130.64M)(209.47M)
Depreciation & Amortization72K(36K)62K26K728K
Deferred Income Tax00000
Stock-Based Compensation7.71M6.05M5.86M7.34M9.4M
Change in Working Capital584K3.9M(957K)3.72M26M
Accounts Receivables(277K)485K31K(200K)(8.81M)
Inventory0000(1.83M)
Accounts Payables623K2.6M2.28M(3.16M)8.42M
Other Working Capital238K816K(3.27M)7.08M28.23M
Other Non-Cash Items9.33M228K(4.06M)14.78M35.83M
Operating Cash Flow(53.5M)(63.67M)(86.46M)(104.77M)(137.51M)
Capital Expenditures(196K)00(28K)0
Acquisitions (Net)9.33M0000
Purchases of Investments(86.44M)(17.82M)(96.45M)00
Sales of Investments86.73M84M52M60M29K
Other Investing Activities(9.33M)005K(29K)
Investing Cash Flow87K66.19M(44.45M)59.97M(9.62M)
Debt Repayment024.15M14.62M(150K)32.42M
Common Stock Issued6.72M27.35M91.42M14.22M230.88M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities162K282K57K40.71M0
Financing Cash Flow6.89M51.78M134.19M54.78M263.31M
Effect of Forex Changes00000
Net Change in Cash(46.53M)54.3M3.29M9.98M116.17M
Free Cash Flow(53.7M)(63.67M)(86.46M)(104.8M)(137.51M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$209.5M
+ D&A$728.0K
+ Stock-Based Comp$9.4M
+ Deferred Tax$0
+ Working Capital$26.0M
+ Other Non-Cash$35.8M
= Operating Cash Flow-$137.5M
- Capex$0
= Free Cash Flow-$137.5M

Analysis

FY2025 free cash flow is -$137.5M. FCF conversion is 65.6% of net income. Operating cash flow was -$137.5M, with capex of $0. The largest bridge item is Other Non-Cash at $35.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
S-8S-8 filingNov 5, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
4Statement of changes in beneficial ownershipNov 5, 2026

Does VSTM generate free cash flow?

Verastem, Inc. (VSTM) generated -$137.51M of free cash flow in fiscal 2025.

How much operating cash flow does VSTM produce?

Operating cash flow was -$137.51M, before capital expenditures of $0.00.